Related references
Note: Only part of the references are listed.Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
Amit M. Oza et al.
LANCET ONCOLOGY (2015)
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Jonathan Ledermann et al.
LANCET ONCOLOGY (2014)
Improving T-Cell Therapy for Epstein-Barr Virus Lymphoproliferative Disorders
Catherine M. Bollard
JOURNAL OF CLINICAL ONCOLOGY (2013)
A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients
Karel Eechoute et al.
CLINICAL CANCER RESEARCH (2012)
A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
Arun Rajan et al.
CLINICAL CANCER RESEARCH (2012)
Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study
Jens Samol et al.
INVESTIGATIONAL NEW DRUGS (2012)
No survival benefit of olaparib in ovarian cancer patients
Neil Bennet
LANCET ONCOLOGY (2012)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan Ledermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours
O. A. Khan et al.
BRITISH JOURNAL OF CANCER (2011)
Poly(ADP-Ribose) Polymerase (PARP) Inhibitors: Exploiting a Synthetic Lethal Strategy in the Clinic
Timothy A. Yap et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations
Konstantin J. Dedes et al.
CELL CYCLE (2011)
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Karen A. Gelmon et al.
LANCET ONCOLOGY (2011)
The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
Thomas Helleday
MOLECULAR ONCOLOGY (2011)
Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective
Shahneen K. Sandhu et al.
EUROPEAN JOURNAL OF CANCER (2010)
The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets
Raga Krishnakumar et al.
MOLECULAR CELL (2010)
Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications
Rupinder K. Sodhi et al.
VASCULAR PHARMACOLOGY (2010)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair
Alan Ashworth
JOURNAL OF CLINICAL ONCOLOGY (2008)
4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
Keith A. Menear et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Sven Rottenberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment
A Trotti et al.
SEMINARS IN RADIATION ONCOLOGY (2003)
Physiology and pathophysiology of poly(ADP-ribosyl)ation
A Bürkle
BIOESSAYS (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
